Delayed
Nasdaq
04:00:00 2019-02-22 pm EST
|
5-day change
|
1st Jan Change
|
6.47
USD
|
-0.31%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
479.4
|
640
|
639.9
|
642.4
|
642.4
|
642.4
|
Enterprise Value (EV)
1 |
316.3
|
457.3
|
-400
|
-12,628
|
-10,596
|
-10,282
|
P/E ratio
|
20.6
x
|
15.8
x
|
6.66
x
|
0.09
x
|
6.49
x
|
-6.09
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.09
x
|
2.6
x
|
1.25
x
|
0.03
x
|
0.43
x
|
1.43
x
|
EV / Revenue
|
1.38
x
|
1.86
x
|
-0.78
x
|
-0.65
x
|
-7.1
x
|
-22.9
x
|
EV / EBITDA
|
6.29
x
|
6.23
x
|
-1.82
x
|
-0.72
x
|
34.5
x
|
26.8
x
|
EV / FCF
|
-56.5
x
|
23.4
x
|
-1.16
x
|
-1.15
x
|
9.08
x
|
74.1
x
|
FCF Yield
|
-1.77%
|
4.27%
|
-86.5%
|
-87%
|
11%
|
1.35%
|
Price to Book
|
1.95
x
|
2.18
x
|
0.86
x
|
0.07
x
|
0.07
x
|
0.07
x
|
Nbr of stocks (in thousands)
|
69,082
|
98,918
|
98,903
|
99,295
|
99,295
|
99,295
|
Reference price
2 |
6.940
|
6.470
|
6.470
|
6.470
|
6.470
|
6.470
|
Announcement Date
|
4/29/19
|
4/30/20
|
4/22/21
|
4/29/22
|
5/1/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
229.6
|
246.1
|
510.6
|
19,375
|
1,493
|
448.3
|
EBITDA
1 |
50.28
|
73.44
|
219.5
|
17,639
|
-307
|
-383.8
|
EBIT
1 |
45.39
|
68.86
|
215.8
|
17,554
|
-460.9
|
-524.3
|
Operating Margin
|
19.77%
|
27.98%
|
42.26%
|
90.6%
|
-30.87%
|
-116.96%
|
Earnings before Tax (EBT)
1 |
46.58
|
70.82
|
216.6
|
17,563
|
25.24
|
-153
|
Net income
1 |
21.78
|
44.93
|
110.4
|
8,467
|
113.9
|
-99.92
|
Net margin
|
9.48%
|
18.26%
|
21.61%
|
43.7%
|
7.63%
|
-22.29%
|
EPS
2 |
0.3365
|
0.4096
|
0.9710
|
74.27
|
0.9973
|
-1.063
|
Free Cash Flow
1 |
-5.602
|
19.54
|
346
|
10,989
|
-1,166
|
-138.7
|
FCF margin
|
-2.44%
|
7.94%
|
67.76%
|
56.72%
|
-78.13%
|
-30.94%
|
FCF Conversion (EBITDA)
|
-
|
26.61%
|
157.64%
|
62.3%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
43.49%
|
313.51%
|
129.78%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/19
|
4/30/20
|
4/22/21
|
4/29/22
|
5/1/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
163
|
183
|
1,040
|
13,270
|
11,238
|
10,924
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.6
|
19.5
|
346
|
10,989
|
-1,166
|
-139
|
ROE (net income / shareholders' equity)
|
15.4%
|
20.2%
|
25.2%
|
193%
|
0.66%
|
-2.09%
|
ROA (Net income/ Total Assets)
|
8.48%
|
10.5%
|
11.5%
|
118%
|
-1.87%
|
-2.36%
|
Assets
1 |
256.8
|
429.1
|
963
|
7,197
|
-6,101
|
4,234
|
Book Value Per Share
2 |
3.560
|
2.970
|
7.520
|
93.70
|
89.70
|
87.40
|
Cash Flow per Share
2 |
2.220
|
1.540
|
10.50
|
117.0
|
43.00
|
12.70
|
Capex
1 |
5.61
|
10.6
|
127
|
720
|
394
|
145
|
Capex / Sales
|
2.44%
|
4.32%
|
24.97%
|
3.72%
|
26.38%
|
32.24%
|
Announcement Date
|
4/29/19
|
4/30/20
|
4/22/21
|
4/29/22
|
5/1/23
|
4/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 642M | | -3.15% | 89.69B | | +2.50% | 41.34B | | -12.55% | 33.72B | | +62.74% | 26.11B | | -20.68% | 14.63B | | -9.05% | 12.84B | | -12.34% | 11.66B | | -43.92% | 11.52B | | +4.27% | 8.92B |
Biopharmaceuticals
|